Novo Nordisk asks FDA to ban compounding pharmacies from making Ozempic, Wegovy copies

The Danish drugmaker Novo Nordisk argues that semaglutide, the active ingredient in Ozempic and Wegovy, are too complex for those manufacturers to make safely.

Read more at CNBC

Save story

Topics

Related

Novo Nordisk asks FDA to block compounding pharmacies from making Ozempic copycats
Politics - The Hill - October 23
Novo Nordisk's Ozempic and Wegovy now available in the U.S. after shortages, FDA says
Business - CNBC - October 30
The Novo Nordisk scientist behind Ozempic, Wegovy weight loss research
Top stories - CBS News - November 4
Novo Nordisk's Wegovy Sales Beat Expectations
Business - The Wall Street Journal - November 6
Novo Nordisk shares jump 8% after Wegovy sales beat expectations
Business - CNBC - November 6
Novo Nordisk Launches Wegovy Weight-Loss Drug in China
Business - The Wall Street Journal - 2 days ago
Ozempic maker Novo Nordisk nudges higher profit forecast
Business - MarketWatch - November 6

More from CNBC

Target's recent trade imports data tells the real story behind massive earnings miss
Business - CNBC - 28 minutes ago
Bitcoin hits fresh record, races toward $100,000 as rally continues
Business - CNBC - 27 minutes ago
Trump and Fed Chair Powell could be set on a collision course over interest rates
Business - CNBC - 1 hour ago
Nvidia says it will sell more of its next-generation Blackwell chips than previously anticipated
Business - CNBC - 14 hours ago
CFPB expands oversight of digital payments services including Apple Pay, Cash App, PayPal and Zelle
Business - CNBC - 20 minutes ago